|
|
Post by kite on Feb 20, 2019 9:00:52 GMT -5
www.globenewswire.com/news-release/2019/02/20/1738408/0/en/MannKind-Corporation-Participating-at-Upcoming-Conferences.htmlWESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be participating at upcoming conferences. 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:00 am (ET) at the Lotte New York Palace, New York, NY. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at www.mannkindcorp.com. BTIG MedTech, Life Science & Diagnostic Tools 2019 Conference February 26-28, 2019 in Snowbird, UT. Participating from the Company will be its Chief Financial Officer, Steven B. Binder, and Chief Commercial Officer, Patrick McCauley in one-on-one meetings connecting management with institutional investors.
|
|
|
|
Post by mnkdfann on Feb 20, 2019 9:05:40 GMT -5
BTIG MedTech, Life Science & Diagnostic Tools 2019 Conference February 26-28, 2019 in Snowbird, UT. Participating from the Company will be its Chief Financial Officer, Steven B. Binder, and Chief Commercial Officer, Patrick McCauley in one-on-one meetings connecting management with institutional investors. Looks like fun. I guess Michael does not ski? www.btig.com/news/btig-medtech-life-science-diagnostic-tools-conference/I see the two events listed in the first post overlap and he can't be everywhere, so maybe he drew the short straw?  |
|
|
|
Post by Thundersnow on Feb 20, 2019 9:16:12 GMT -5
BTIG MedTech, Life Science & Diagnostic Tools 2019 Conference February 26-28, 2019 in Snowbird, UT. Participating from the Company will be its Chief Financial Officer, Steven B. Binder, and Chief Commercial Officer, Patrick McCauley in one-on-one meetings connecting management with institutional investors. Looks like fun. I guess Michael does not ski? www.btig.com/news/btig-medtech-life-science-diagnostic-tools-conference/I see the two events listed in the first post overlap and he can't be everywhere, so maybe he drew the short straw? When I read this I let out a BIG SIGH.....First thing that I thought about is that MNKD is not playing with the TOP TIER MONEY GUYS. They are still in the TOXIC FINANCING Arena. Very disappointing. |
|
|
|
Post by Clement on Feb 20, 2019 9:17:10 GMT -5
Mannkind EC is before (or at the beginning) of these events. |
|
|
|
Post by #NoMoreNeedles on Feb 20, 2019 9:25:43 GMT -5
|
|
|
|
Post by sportsrancho on Feb 20, 2019 9:28:12 GMT -5
Yep, I guess we’ll see how the market takes this news:-( |
|
|
|
Post by xanet on Feb 20, 2019 9:34:28 GMT -5
Yep, I guess we’ll see how the market takes this news:-( Do you think the market will react at all? I would assume participation in this is part of a package that included the December financing, which they managed. That seems expected, and I would think would be priced in. |
|
|
|
Post by Clement on Feb 20, 2019 9:40:48 GMT -5
Robert (Bert) Hazlett is a Managing Director and Biotechnology Equity Research Analyst at BTIG.
He asked questions at Mannkind conference call on Jan 4. Sounded positive.
research.btig.com/analysts/robert-bert-hazlett/
|
|
|
|
Post by bigchungus91354 on Feb 20, 2019 9:43:36 GMT -5
What is their goal for these conferences, to ultimately, sell more shares?
|
|
|
|
Post by Clement on Feb 20, 2019 9:55:16 GMT -5
I would like Bert Hazlett to announce coverage of MNKD with price target of $10.
|
|
|
|
Post by #NoMoreNeedles on Feb 20, 2019 9:57:01 GMT -5
Robert “Bert” Hazlett asked ONE question!
Operator
We’ll take the next question from left from Bert Hazlett from BTIG. Please go ahead. Your line is open.
Bert Hazlett
Yes, thank you for taking the question. Thanks for the update. A number of the elements were discussed already, but a quick just follow on the strategic development. Has the possible deal supports incremental interest from potential stakeholders in the industry. It certainly has from investors, but I’m just intrigued by whether the temperature or the types of discussion have increased once you have done that very intriguing deal. Thanks.
...
Bert Hazlett
Thanks. Look forward to progress with the platform and with Afrezza as well. Thanks so much.
|
|
|
|
Post by Clement on Feb 20, 2019 10:05:05 GMT -5
Yep. Great response by Mike re Technosphere platform.
|
|
|
|
Post by bigchungus91354 on Feb 20, 2019 10:10:36 GMT -5
Robert “Bert” Hazlett asked ONE question! Operator We’ll take the next question from left from Bert Hazlett from BTIG. Please go ahead. Your line is open. Bert Hazlett Yes, thank you for taking the question. Thanks for the update. A number of the elements were discussed already, but a quick just follow on the strategic development. Has the possible deal supports incremental interest from potential stakeholders in the industry. It certainly has from investors, but I’m just intrigued by whether the temperature or the types of discussion have increased once you have done that very intriguing deal. Thanks. ... Bert Hazlett Thanks. Look forward to progress with the platform and with Afrezza as well. Thanks so much. LOL. Do you think they will give Mike K another crack at it, or is he banned from the Q&A? |
|
|
|
Post by jred on Feb 20, 2019 10:31:33 GMT -5
Once Deerfield gets paid $2.5M in May and then $9M in July their convertible debt is done. That frees up the Danbury facility to possibly use as collateral in some type of financing to raise cash if needed.
|
|
|
|
Post by mannmade on Feb 20, 2019 10:34:14 GMT -5
I am not so sure about that. As I recall someone mentioned that mnkd assets also tied to milestone payments. However I Have not confirmed.
|
|
